BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The company delivered record-breaking revenues in 2024 and Q1 2025, including $72.5 million in net revenue for Q1 — a 73% increase over the prior year — and six consecutive quarters of positive adjusted EBITDA.
With cash reserves rising to $30.8 million and a growing patent portfolio of 58 issued and 68 pending patents, BSEM is scaling profitably while advancing its proprietary BioREtain® technology, which has shown clinically superior results for chronic, non-healing wounds.
National recognition is adding to the momentum, with CEO Jason Matuszewski named EY Entrepreneur of the Year 2025 Florida Award winner, validating the leadership driving this high-growth MedTech powerhouse.
The company's outlook is equally compelling. CMS national reimbursement for Vendaje AC®, ongoing pivotal clinical trials, strategic acquisitions, and a potential Nasdaq uplisting position BSEM to capture multi-billion-dollar markets in diabetic and surgical wound care.
Analysts at Zacks Small Cap Research have set a $25.50 price target , citing strong management execution and smart growth strategy. With record revenues, clinical breakthroughs, and regulatory milestones, BioStem is poised for explosive growth in the regenerative medicine sector.
Discover how BSEM is transforming wound care, driving profitability, and positioning itself for the next stage of MedTech domination.
This message is a PAID ADVERTISEMENT for BioStem Technologies Inc (OTC: BSEM) from Sideways Frequency. StockEarnings, Inc. has received a fixed fee of $6000 from Sideways Frequency for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between October 17, 2025 and October 23, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies Inc (OTC: BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies Inc (OTC: BSEM).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
0 Response to "Leading the MedTech Charge with Record Revenue and Nasdaq Potential 🔥"
Post a Comment